+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunotherapy Drugs: Global Markets- Product Image
Immunotherapy Drugs: Global Markets- Product Image
New

Immunotherapy Drugs: Global Markets

  • PDF Icon

    Report

  • 231 Pages
  • November 2025
  • Region: Global
  • BCC Research
  • ID: 6191171
Description Jump to:
The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030. It has existed since the 1800s, but research has been slow due to a limited understanding of the immune system. Immunotherapy can lead to long-lasting effects, including remissions or cures for advanced cancers. However, it can also cause side effects, including fatigue, skin rash and lung inflammation. Despite these challenges, the field is rapidly evolving, with researchers developing more effective approaches such as personalized cancer vaccines and oncolytic viruses. Immunotherapy has demonstrated its potential for multiple diseases, particularly cancer, with ongoing research likely to yield even more effective and personalized therapies.

Report Scope

The current report provides detailed information on immunotherapy drugs. It analyzes the market trends with data from 2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) from 2025 through 2030, including regional markets for immunotherapy drugs. This report highlights the current and future market potential and provides a detailed discussion on the competitive environment. The report will also cover regulatory scenarios, drivers, restraints and opportunities. Additionally, it covers market share data for key companies.

The market in this report is segmented by immunotherapy type into checkpoint inhibitors, monoclonal antibodies (mAbs) and cytokine therapy. MAbs are sub-segmented into naked mAbs, conjugated mAbs and bispecific mAbs. Checkpoint inhibitors are sub-segmented into programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3).

By application, the market is segmented into cancer, autoimmune diseases and chronic inflammatory diseases.

By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The regional segment will cover a detailed analysis of the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. Market data is provided for 2024 the base year, with forecasts for 2025 and a forecast value for 2030.

The report aims to:
  • Analyze types of immunotherapies.
  • Analyze global market size and segmentation.
  • Understand market constraints and drivers.
  • Provide detailed market forecasts through 2030.
  • Assess market shares, competitiveness and industry structure.
  • Identify potential long-term impacts on the immunotherapy drug market.

The report includes:

  • 88 data tables and 57 additional tables
  • An overview of the global market for immunotherapy drugs
  • In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, and forecasts for 2030, including projections of CAGRs through 2030
  • Evaluation of the current market size and revenue growth prospects specific to the immunotherapy drugs, accompanied by a market share analysis by therapy type, application and region
  • Description of immunotherapy and combination immunotherapy, and discussion of how it targets cell-mediated adaptive immunity
  • Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and new targeted approaches for immunotherapy
  • Analysis of the current and future demands in the global immunotherapy drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
  • Analysis of drivers, challenges and opportunities affecting the market’s growth
  • Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
  • Market share analysis of the key companies in the immunotherapy drugs, along with their research priorities, product portfolios, global rankings and the competitive landscape
  • Profiles of major companies in industry, including: F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, and Sanofi

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
  • Market Dynamics and Growth Factors
  • Emerging Technologies
  • Segmental Analysis
  • Regional Analysis
  • Conclusion
Chapter 2 Market Overview
  • Overview
  • Macroeconomic Factor Analysis
  • Impact of U.S. Tariffs on the Pharmaceutical Industry
  • Healthcare Expenditure
  • Impact of GDP on the Pharma Sector
  • Porter's Five Forces Analysis
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Potential for New Entrants
  • Threat of Substitutes
  • Competitiveness in the Industry
Chapter 3 Market Dynamics
  • Market Dynamics
  • Market Drivers
  • Increasing Incidence of Chronic Diseases
  • Increasing R&D Spending by Market Players
  • Rise in Government Funding and Pharmaceutical R&D Spending
  • Market Restraints
  • High Cost of Immunotherapy Drugs
  • Rising Generic Competition
  • Lack of Skilled Professionals
  • Market Opportunities
  • Technological Advances in Immunotherapy
  • Potential in Immunotherapy
Chapter 4 Regulatory Landscape
  • Overview
  • U.S.
  • Europe
  • Asia-Pacific
Chapter 5 Emerging Technologies and Pipeline Analysis
  • Overview
  • AI and ML
  • Emergent Biomarkers
  • Genome Editing and CRISPR
  • Pipeline Analysis
  • Key Takeaways
  • Patent Analysis
  • Key Takeaways
Chapter 6 Market Segment Analysis
  • Segmentation Breakdown
  • Global Market for Immunotherapy Drugs, by Therapy Type
  • Key Takeaways
  • Monoclonal Antibodies
  • Checkpoint Inhibitors
  • Cytokines
  • Others
  • Global Immunotherapy Drug Market, by Application
  • Key Takeaways
  • Cancer
  • Autoimmune Diseases
  • Chronic Inflammatory Respiratory Condition
  • Geographic Breakdown
  • Global Market for Immunotherapy Drugs by Region
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa
Chapter 7 Competitive Intelligence
  • Key Takeaways
  • Competitive Landscape
  • Company Share Analysis
Chapter 8 Sustainability in Immunotherapy Drugs Market: An ESG Perspective
  • Introduction to ESG
  • Sustainability in the Immunotherapy Drug Market
  • ESG Perspective
  • Environmental Impact
  • Social Impact
  • Governance Impact
  • ESG Risk Ratings
  • Conclusion
Chapter 9 Appendix
  • Methodology
  • Abbreviations
  • Sources
  • Company Profiles
  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BRISTOL-MYERS SQUIBB CO.
  • F. HOFFMANN-LA ROCHE LTD.
  • GILEAD SCIENCES INC.
  • GSK PLC.
  • JOHNSON & JOHNSON SERVICES INC.
  • LILLY
  • MERCK & CO.INC.
  • NOVARTIS AG
  • PFIZER INC.
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • Emerging Players in the Immunotherapy Drugs Market
List of Tables
Summary Table: Global Market for Immunotherapy Drugs, by Region, Through 2030
Table 1: Health Expenditure
Table 2: Rheumatoid Arthritis: Level 3 Cause, 2021
Table 3: Average Price of Immunotherapy
Table 4: List of Selected Clinical Trials Studies on Immunotherapy
Table 5: List of Selected Recent Patents Related to Immunotherapy Drugs, January 2024-June 2025
Table 6: Global Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 7: Global Market for Monoclonal Antibodies in Immunotherapy Drugs, by Type, Through 2030
Table 8: Global Market for Monoclonal Antibodies in Immunotherapy Drugs, by Region, Through 2030
Table 9: FDA-Approved Immune Checkpoint Inhibitors, 2022
Table 10: Global Market for Checkpoint Inhibitors in Immunotherapy Drugs, by Type, Through 2030
Table 11: Global Market for Checkpoint Inhibitors in Immunotherapy Drugs, by Region, Through 2030
Table 12: Global Market for Cytokines in Immunotherapy Drugs, by Type, Through 2030
Table 13: Global Market for Cytokines in Immunotherapy Drugs, by Region, Through 2030
Table 14: Players Investing in Oncolytic Virology
Table 15: Approved CAR-T Products, 2017-2025
Table 16: Global Market for Other Therapy Types in Immunotherapy Drugs, by Region, Through 2030
Table 17: Global Market for Immunotherapy Drugs, by Application, Through 2030
Table 18: Global Market for Immunotherapy Drugs in Cancer, by Region, Through 2030
Table 19: Global Market for Immunotherapy Drugs in Autoimmune Diseases, by Region, Through 2030
Table 20: Global Market for Immunotherapy Drugs in Chronic Inflammatory Respiratory Diseases, by Region, Through 2030
Table 21: Global Market for Immunotherapy Drugs in Other Diseases, by Region, Through 2030
Table 22: Global Market for Immunotherapy Drugs, by Region, Through 2030
Table 23: North American Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 24: North American Market for Immunotherapy Drugs, by Application, Through 2030
Table 25: North American Market for Immunotherapy Drugs, by Country, Through 2030
Table 26: U.S. Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 27: U.S. Market for Immunotherapy Drugs, by Application, Through 2030
Table 28: Canadian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 29: Canadian Market for Immunotherapy Drugs, by Application, Through 2030
Table 30: Mexican Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 31: Mexican Market for Immunotherapy Drugs, by Application, Through 2030
Table 32: European Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 33: European Market for Immunotherapy Drugs, by Application, Through 2030
Table 34: European Market for Immunotherapy Drugs, by Country, Through 2030
Table 35: German Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 36: German Market for Immunotherapy Drugs, by Application, Through 2030
Table 37: U.K. Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 38: U.K. Market for Immunotherapy Drugs, by Application, Through 2030
Table 39: French Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 40: French Market for Immunotherapy Drugs, by Application, Through 2030
Table 41: Italian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 42: Italian Market for Immunotherapy Drugs, by Application, Through 2030
Table 43: Spanish Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 44: Spanish Market for Immunotherapy Drugs, by Application, Through 2030
Table 45: Rest of Europe Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 46: Rest of Europe Market for Immunotherapy Drugs, by Application, Through 2030
Table 47: Recently Approved Immunotherapies in Asian Countries, 2021-2024
Table 48: Asia-Pacific Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 49: Asia-Pacific Market for Immunotherapy Drugs, by Application, Through 2030
Table 50: Asia-Pacific Market for Immunotherapy Drugs, by Country, Through 2030
Table 51: Chinese Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 52: Chinese Market for Immunotherapy Drugs, by Application, Through 2030
Table 53: Japanese Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 54: Japanese Market for Immunotherapy Drugs, by Application, Through 2030
Table 55: Indian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 56: Indian Market for Immunotherapy Drugs, by Application, Through 2030
Table 57: South Korean Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 58: South Korean Market for Immunotherapy Drugs, by Application, Through 2030
Table 59: Australian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 60: Australian Market for Immunotherapy Drugs, by Application, Through 2030
Table 61: Rest of Asia-Pacific Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 62: Rest of Asia-Pacific Market for Immunotherapy Drugs, by Application, Through 2030
Table 63: South American Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 64: South American Market for Immunotherapy Drugs, by Application, Through 2030
Table 65: South American Market for Immunotherapy Drugs, by Country, Through 2030
Table 66: Brazilian Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 67: Brazilian Market for Immunotherapy Drugs, by Application, Through 2030
Table 68: Argentine Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 69: Argentine Market for Immunotherapy Drugs, by Application, Through 2030
Table 70: Rest of South America Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 71: Rest of South America Market for Immunotherapy Drugs, by Application, Through 2030
Table 72: MEA Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 73: MEA Market for Immunotherapy Drugs, by Application, Through 2030
Table 74: MEA Market for Immunotherapy Drugs, by Sub-Region, Through 2030
Table 75: Middle Eastern Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 76: Middle Eastern Market for Immunotherapy Drugs, by Application, Through 2030
Table 77: African Market for Immunotherapy Drugs, by Therapy Type, Through 2030
Table 78: African Market for Immunotherapy Drugs, by Application, Through 2030
Table 79: News/Key Developments in the Immunotherapy Drug Market, 2023-2025
Table 80: Key Focus Areas in ESG Metrics
Table 81: ESG Rankings for Leading Companies in Immunotherapy Drugs Market, 2025*
Table 82: Abbreviations Used in this Report
Table 83: Report Sources
Table 84: AbbVie Inc.: Company Snapshot
Table 85: AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 86: AbbVie Inc.: Product Portfolio
Table 87: AbbVie Inc.: News/Key Developments, 2023-2025
Table 88: Amgen Inc.: Company Snapshot
Table 89: Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 90: Amgen Inc.: Product Portfolio
Table 91: Amgen Inc.: News/Key Developments, 2022-2025
Table 92: AstraZeneca: Company Snapshot
Table 93: AstraZeneca: Financial Performance, FY 2023 and 2024
Table 94: AstraZeneca: Product Portfolio
Table 95: AstraZeneca: News/Recent Developments, 2023-2024
Table 96: Bristol-Myers Squibb Co.: Company Snapshot
Table 97: Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2024
Table 98: Bristol-Myers Squibb Co.: Product Portfolio
Table 99: Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
Table 100: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 101: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 102: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 103: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
Table 104: Gilead Sciences Inc.: Company Snapshot
Table 105: Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 106: Gilead Sciences Inc.: Product Portfolio
Table 107: Gilead Sciences Inc.: News/Key Developments, 2023-2025
Table 108: GSK Plc: Company Snapshot
Table 109: GSK Plc: Financial Performance, FY 2023 and 2024
Table 110: GSK Plc: Product Portfolio
Table 111: GSK Plc: News/Key Developments, 2022-2025
Table 112: Johnson & Johnson Services Inc.: Company Snapshot
Table 113: Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
Table 114: Johnson & Johnson Services Inc.: Product Portfolio
Table 115: Johnson & Johnson Services Inc.: News/Key Developments, 2022-2025
Table 116: Lilly: Company Snapshot
Table 117: Lilly: Financial Performance, FY 2023 and 2024
Table 118: Lilly: Product Portfolio
Table 119: Lilly: News/Key Development, 2022-2025
Table 120: Merck & Co. Inc.: Company Snapshot
Table 121: Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 122: Merck & Co. Inc.: Product Portfolio
Table 123: Merck & Co. Inc.: News/Key Developments, 2021-2025
Table 124: Novartis AG: Company Snapshot
Table 125: Novartis AG: Financial Performance, FY 2023 and 2024
Table 126: Novartis AG: Product Portfolio
Table 127: Novartis AG: News/Key Developments, 2022-2024
Table 128: Pfizer Inc.: Company Snapshot
Table 129: Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 130: Pfizer Inc.: Product Portfolio
Table 131: Pfizer Inc.: News/Key Developments, 2022-2025
Table 132: Sanofi: Company Snapshot
Table 133: Sanofi: Financial Performance, FY 2023 and 2024
Table 134: Sanofi: Product Portfolio
Table 135: Sanofi: News/Key Developments, 2022-2025
Table 136: Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 137: Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 138: Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 139: Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023-2025
Table 140: Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 141: Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 142: Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 143: Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2024- 2025
Table 144: Some Emerging Players in the Immunotherapy Drugs Market
List of Figures
Summary Figure: Global Market Shares of Immunotherapy Drugs, by Region, 2024
Figure 1: Porter's Five Forces Analysis of the Immunotherapy Drugs Market
Figure 2: Market Dynamics of Immunotherapy Drugs
Figure 3: Distribution Share of the Most Frequent Cancer Types in Women*, 2022
Figure 4: Distribution Share of the Most Frequent Cancer Types in Men*, 2022
Figure 5: Estimated New Cancer Cases and Deaths in the U.S., 2024
Figure 6: Companies' R&D Expenditure, by Function, 2022
Figure 7: National Cancer Institute Research Funding, 2012-2019
Figure 8: Global Pharmaceutical R&D Spending and Growth, 2020-2026
Figure 9: Immunotherapy-Related Patents and Publications in the U.S. and China
Figure 10: Global Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 11: Global Market Shares of Monoclonal Antibodies in Immunotherapy Drugs, by Type, 2024
Figure 12: Global Market Shares of Monoclonal Antibodies in Immunotherapy Drugs, by Region, 2024
Figure 13: Global Market Shares of Checkpoint Inhibitors in Immunotherapy Drugs, by Type, 2024
Figure 14: Global Market Shares of Checkpoint Inhibitors in Immunotherapy Drugs, by Region, 2024
Figure 15: Global Market Shares of Cytokines in Immunotherapy Drugs, by Type, 2024
Figure 16: Global Market Shares of Cytokines in Immunotherapy Drugs, by Region, 2024
Figure 17: Global Market Shares of Other Therapy Types in Immunotherapy Drugs, by Region, 2024
Figure 18: Global Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 19: Global Market Shares of Immunotherapy Drugs in Cancer, by Region, 2024
Figure 20: Global Market Shares of Immunotherapy Drugs in Autoimmune Diseases, by Region, 2024
Figure 21: Global Market Shares of Immunotherapy Drugs in Chronic Inflammatory Respiratory Diseases, by Region, 2024
Figure 22: Global Market Shares of Immunotherapy Drugs in Other Diseases, by Region, 2024
Figure 23: Global Market Shares of Immunotherapy Drugs, by Region, 2024
Figure 24: North American Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 25: North American Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 26: North American Market Shares of Immunotherapy Drugs, by Country, 2024
Figure 27: U.S. Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 28: U.S. Market Shares of Immunotherapy Drugs Market, by Application, 2024
Figure 29: Canadian Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 30: Canadian Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 31: Mexican Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 32: Mexican Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 33: European Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 34: European Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 35: European Market Shares of Immunotherapy Drugs, by Country, 2024
Figure 36: German Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 37: German Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 38: U.K. Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 39: U.K. Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 40: French Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 41: French Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 42: Italian Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 43: Italian Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 44: Spanish Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 45: Spanish Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 46: Rest of Europe Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 47: Rest of Europe Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 48: Asia-Pacific Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 49: Asia-Pacific Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 50: Asia-Pacific Market Shares of Immunotherapy Drugs, by Country, 2024
Figure 51: Chinese Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 52: Chinese Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 53: Japanese Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 54: Japanese Market Shares of Immunotherapy Drugs Market, by Application, 2024
Figure 55: Indian Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 56: Indian Market Shares of Immunotherapy Drugs Market, by Application, 2024
Figure 57: South Korean Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 58: South Korean Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 59: Australian Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 60: Australian Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 61: Rest of Asia-Pacific Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 62: Rest of Asia-Pacific Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 63: South American Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 64: South American Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 65: South American Market Shares of Immunotherapy Drugs, by Country, 2024
Figure 66: Brazilian Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 67: Brazilian Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 68: Argentine Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 69: Argentine Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 70: Rest of South America Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 71: Rest of South America Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 72: MEA Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 73: MEA Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 74: MEA Market Shares of Immunotherapy Drugs, by Sub-Region, 2024
Figure 75: Middle Eastern Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 76: Middle Eastern Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 77: African Market Shares of Immunotherapy Drugs, by Therapy Type, 2024
Figure 78: African Market Shares of Immunotherapy Drugs, by Application, 2024
Figure 79: Leading 10 Blockbuster Immunotherapy Drugs, by Sales Revenue, 2023 and 2024
Figure 80: Global Market Shares of Immunotherapy Drugs, by Company, 2024
Figure 81: Pillars of ESG
Figure 82: Advantages of ESG for Companies
Figure 83: AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 84: AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 85: Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 86: Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 87: AstraZeneca: Revenue Shares, by Business Unit, FY 2024
Figure 88: AstraZeneca: Revenue Shares, by Region/Country, FY 2024
Figure 89: Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 90: Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 91: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 92: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 93: Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 94: Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 95: GSK Plc: Revenue Shares, by Business Unit, FY 2024
Figure 96: GSK Plc: Revenue Shares, by Country/Region, FY 2024
Figure 97: Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 98: Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 99: Lilly: Revenue Shares, by Business Unit, FY 2024
Figure 100: Lilly: Revenue Shares, by Country/Region, FY 2024
Figure 101: Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 102: Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 103: Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 104: Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 105: Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 106: Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 107: Sanofi: Revenue Shares, by Country/Region, FY 2024
Figure 108: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 109: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Region, FY 2024
Figure 110: Teva Pharmaceutical Industries Ltd.: Market Shares, by Country/Region, FY 2024

Companies Mentioned

  • Abbvie Inc.
  • Amgen Inc.
  • Astrazeneca
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Gsk PLC.
  • Johnson & Johnson Services Inc.
  • Lilly
  • Merck & Co.Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages231
PublishedNovember 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 260.7 Billion
Forecasted Market Value ( USD ) by 2030 $ 467.4 Billion
Compound Annual Growth Rate12.4%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Cancer Immunotherapy: Technologies and Global Markets - Product Image

Cancer Immunotherapy: Technologies and Global Markets

  • Report
  • 203 Pages
  • Global
From
Oncology Pharmaceuticals Market - Product Image

Oncology Pharmaceuticals Market

  • Report
  • 181 Pages
  • Global
From
Immunotherapy Drugs Market Size, Share & Trends by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Forecast to 2029 - Product Image

Immunotherapy Drugs Market Size, Share & Trends by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Forecast to 2029

  • Report
  • 335 Pages
  • Global
From
Immunotherapy Drugs Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Type, Application, and End-user - Product Image

Immunotherapy Drugs Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Type, Application, and End-user

  • Report
  • 118 Pages
  • Global
From
Drugs for Immunotherapy Market Report 2025 - Product Image

Drugs for Immunotherapy Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.